Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (IBRX)
NASDAQ:IBRX
Holding IBRX?
Track your performance easily
IBRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.67 - $10.53
Previous Close$5.42
Volume4.54M
Average Volume (3M)4.81M
Market Cap
$3.78B
Enterprise Value$4.56B
Total Cash (Recent Filing)$217.98M
Total Debt (Recent Filing)$998.94M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Aug 09, 2023EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding696,533,418
10 Day Avg. Volume15,230,105
30 Day Avg. Volume4,810,962
Standard Deviation0.36
R-Squared0.02
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)-5.30
Price to Sales (P/S)2886.25
Price to Cash Flow (P/CF)-9.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.48K
Enterprise Value/Gross Profit7.33K
Enterprise Value/Ebitda-12.57
Forecast
1Y Price Target
$14.25Price Target Upside168.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
ImmunityBio News
Ownership Overview
51.67% Insiders
2.73% Mutual Funds
0.45% Other Institutional Investors
40.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IBRX FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $2.67 and its highest was $10.53 in the past 12 months.
What is ImmunityBio’s market cap?
Currently, no data Available
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is Aug 09, 2023 which is 457 days ago.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on May 11, 2023. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.27.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -$0.24.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 696,533,450 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -$0.27 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.215%.
Which hedge fund is a major shareholder of ImmunityBio?
Among the largest hedge funds holding ImmunityBio’s share is Woodline Partners LP. It holds ImmunityBio’s shares valued at 3M.
---
ImmunityBio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.25 (168.87% Upside)
$14.25 (168.87% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 90%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 633.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 13.7%
Last 30 Days ▲ 13.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
50.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
52.57%
Trailing 12-Months
Company Description
ImmunityBio
NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.
---
IBRX Stock 12 Month Forecast
Average Price Target
$14.25
▲(168.87% Upside)
Technical Analysis
Best Analysts Covering IBRX
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
+37.04%
reiterated a buy rating 3 months ago
Copying Kelly Shi's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +37.04% per trade.
---